When my 80-year-old father was diagnosed with Hodgkin’s disease, he was so weak that he could no longer walk, and his oncologist worried that chemotherapy might do more harm than good. But there was a new drug available, a “targeted therapy” that uses antibodies to destroy cancer cells while apparently leaving the rest of the patient’s cells alone.